The detection of neural autoantibodies in patients with antiepileptic-drug-resistant epilepsy predicts response to immunotherapy

European Journal of Neurology

Volumn 22, Issue 1, 2015, Pages 70-78

  Iorio, R ^a,b   Assenza, G ^c   Tombini, M ^c   Colicchio, G ^b   Della Marca, G ^b   Benvenga, A ^c   Damato, V ^b   Rossini, P M ^b   Vollono, C ^b   Plantone, D ^b   Marti, A ^b   Batocchi, A P ^b   Evoli, A ^b  

^a IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Antiepileptic drug resistant epilepsy; Autoimmune epilepsy; Leucine rich glioma inactivated 1; Synaptic antigens

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR ANTIBODY; ANTICONVULSIVE AGENT; AUTOANTIBODY; AZATHIOPRINE; GLUTAMATE DECARBOXYLASE 65; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; HU ANTIBODY; IMMUNOGLOBULIN; LEUCINE RICH GLIOMA INACTIVATED PROTEIN 1 ANTIBODY; METHYLPREDNISOLONE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR ANTIBODY; PREDNISONE; RITUXIMAB; UNCA ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANIMAL TISSUE; ARTICLE; BRAIN; CONTROLLED STUDY; DISEASE DURATION; ELECTROENCEPHALOGRAPHY; EPILEPSY; FEMALE; FROZEN SECTION; HEK293 CELL LINE; HUMAN; IMMUNOFLUORESCENCE; IMMUNOREACTIVITY; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MOUSE; NEUROLOGIC DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMAPHERESIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; ANIMAL; BLOOD; CEREBROSPINAL FLUID; DRUG RESISTANCE; IMMUNOLOGY; MIDDLE AGED; PROCEDURES; TREATMENT OUTCOME;

ADULT; ANIMALS; ANTICONVULSANTS; AUTOANTIBODIES; DRUG RESISTANCE; EPILEPSY; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MICE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84923105236     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12529     Document Type: Article

References (27)

1. Theodore WH, Spencer SS, Wiebe S, et al. Epilepsy in North America: a report prepared under the auspices of the global campaign against epilepsy, the International Bureau for Epilepsy, the International League Against Epilepsy, and the World Health Organization. Epilepsia 2006; 47: 1700-1722.
2. Forsgren L, Beghi E, Õun A, Sillanpää M. The epidemiology of epilepsy in Europe - a systematic review. Eur J Neurol 2005; 12: 245-253.
3. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000; 342: 314-319.
4. Berg AT, Scheffer IE. New concepts in classification of the epilepsies: entering the 21st century. Epilepsia 2011; 52: 1058-1062.
5. Peltola J, Kulmala P, Isojärvi J, et al. Autoantibodies to glutamic acid decarboxylase in patients with therapy-resistant epilepsy. Neurology 2000; 55: 46-50.
6. McKnight K, Jiang Y, Hart Y, et al. Serum antibodies in epilepsy and seizure-associated disorders. Neurology 2005; 65: 1730-1736.
7. Falip M, Carreño M, Miró J, et al. Prevalence and immunological spectrum of temporal lobe epilepsy with glutamic acid decarboxylase antibodies. Eur J Neurol 2012; 19: 827-833.
8. Iorio R, Lennon VA. Neural antigen-specific autoimmune disorders. Immunol Rev 2012; 248: 104-121.
9. Davis R, Dalmau J. Autoimmunity, seizures, and status epilepticus. Epilepsia 2013; 54(Suppl. 6): 46-49.
10. Vincent A, Irani SR, Lang B. Potentially pathogenic autoantibodies associated with epilepsy and encephalitis in children and adults. Epilepsia 2011; 52(Suppl. 8): 8-11.
11. Vincent A, Bien CG, Irani SR, Waters P. Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol 2011; 10: 759-772.
12. Niehusmann P, Dalmau J, Rudlowski C, et al. Diagnostic value of N-methyl-D-aspartate receptor antibodies in women with new-onset epilepsy. Arch Neurol 2009; 66: 458-464.
13. Lai M, Hughes EG, Peng X, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol 2009; 65: 424-434.
14. Lancaster E, Lai M, Peng X, et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol 2010; 9: 67-76.
15. Irani SR, Michell AW, Lang B, et al. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol 2011; 69: 892-900.
16. Quek AM, Britton JW, McKeon A, et al. Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch Neurol 2012; 69: 582-593.
17. Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010; 51: 1069-1077.
18. Lancaster E, Martinez-Hernandez E, Titulaer MJ, et al. Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome. Neurology 2011; 77: 1698-1701.
19. Boronat A, Gelfand JM, Gresa-Arribas N, et al. Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels. Ann Neurol 2013; 73: 120-128.
20. Petit-Pedrol M, Armangue T, Peng X, et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol 2014; 13: 276-286.
21. Brenner T, Sills GJ, Hart Y, et al. Prevalence of neurologic autoantibodies in cohorts of patients with new and established epilepsy. Epilepsia 2013; 54: 1028-1035.
22. Fukata Y, Lovero KL, Iwanaga T, et al. Disruption of LGI1-linked synaptic complex causes abnormal synaptic transmission and epilepsy. Proc Natl Acad Sci U S A 2010; 107: 3799-3804.
23. Ohkawa T, Fukata Y, Yamasaki M, et al. Autoantibodies to epilepsy-related LGI1 in limbic encephalitis neutralize LGI1-ADAM22 interaction and reduce synaptic AMPA receptors. J Neurosci 2013; 33: 18161-18174.
24. McKeon A. Immunotherapeutics for autoimmune encephalopathies. Curr Treat Options Neurol 2013; 15: 723-737.
25. Lancaster E, Martinez-Hernandez E, Dalmau J. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology 2011; 77: 179-189.
26. Bien CG. Value of autoantibodies for prediction of treatment response in patients with autoimmune epilepsy: review of the literature and suggestions for clinical management. Epilepsia 2013; 54(Suppl. 2): 48-55.
27. Toledano M, Britton JW, McKeon A, et al. Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy. Neurology 2014; 82: 1578-1586.